San Antonio Breast Cancer Symposium

Patients with triple-negative breast cancer who have residual disease after receiving neoadjuvant chemotherapy have a series of genetic alterations that are clinically targetable and may warrant further study.

Kapil N. Bhalla, MD, from the University of Kansas Cancer Center, describes an in vivo study that examined treatment with histone deacetylase inhibitors in triple-negative breast cancer cells.

Stefan Aebi, MD, from the Luzerner Kantonsspital, Switzerland, discusses findings from the CALOR trial that examined the administration of adjuvant chemotherapy for women recurrent breast cancer.

Preliminary research suggests that in-vitro exposure to an HDAC inhibitor may sensitize triple-negative breast cancer cells to treatment with a PARP inhibitor and cisplatin.

Adjuvant chemotherapy improved survival rates in women with isolated local or regional breast cancer recurrence, according to results from the CALOR trial.

Postmenopausal women with advanced estrogen receptor–positive breast cancer lived longer when they received a 500-mg dose of fulvestrant as compared with a 250-mg dose.

Combining the investigational PD 0332991 with letrozole as first-line therapy extended progression-free survival in women with advanced estrogen-receptor positive breast cancer.

Sentinel lymph node surgery may provide a less-invasive alternative to axillary lymph node dissection for nodal staging in node-positive breast cancer.

Extending the duration of adjuvant tamoxifen treatment to 10 years was more effective than the standard 5 years of treatment in protecting against recurrence and death among women with ER+ breast cancer.

Richard Finn, MD, from the Jonsson Comprehensive Cancer Center, describes results from a phase II study that examined PD 0332991 in combination with letrozole for women with metastatic ER-positive breast cancer.

Hope S. Rugo, MD, from the UCSF Helen Diller Family Comprehensive Cancer Center, previews the 2012 San Antonio Breast Cancer Symposium program.

A study of bevacizumab in women with HER2-positive metastatic breast cancer demonstrated that combining the drug with standard therapy improves PFS.

A collection of photos from the 34th annual SABCS at the Henry B. Gonzalez Convention Center in San Antonio, TX, from December 6-10, 2011.

Carriers of the BRCA1 or BRCA2 mutation are at greater risk for developing a new primary tumor in the contralateral breast compared with noncarriers.

Dr. José Baselga from Massachusetts General Hospital Discusses the CLEOPATRA Pertuzumab Trial

Tumor-related factors that lead to chemotherapy resistance in Hispanic women make them more likely to die from breast cancer than non-Hispanic whites.

Dr. Debu Tripathy from USC Norris Comprehensive Cancer Center Discusses the AVEREL Bevacizumab Trial Results

The CLEOPATRA trial marks the first time that dual inhibitors have demonstrated value in the treatment of HER2-positive metastatic breast cancer.

Dr. Gabriel Hortobagyi from the MD Anderson Cancer Center Discusses the BOLERO-2 Trial

The BOLERO-2 trial suggests that adding everolimus to hormonal therapy can overcome resistance in patients whose disease progressed.

A large study of HER2+ breast cancer patients shows that obese patients had worse outcomes than normal weight or overweight patients.

Dr. Edith Perez from the Mayo Clinic Cancer Center Discusses the CLEOPATRA Pertuzumab Trial

The results of 2 studies likely to have a significant impact upon the treatment of women with metastatic breast cancer.

Dr. Benjamin Smith from MD Anderson Cancer Center Discusses the Brachytherapy Breast Cancer Trial

A new 12-gene assay for predicting risk of recurrence for patients with ductal carcinoma in situ (DCIS).

Dr. Lawrence Solin from Einstein Medical Center Discusses the DCIS Score Recurrence Test

It may be possible to predict which women with HR+ invasive breast cancer will experience recurrence by using a series of gene expression profiles.